Focused On-demand Library for Forkhead box protein G1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P55316

UPID:

FOXG1_HUMAN

Alternative names:

Brain factor 1; Brain factor 2; Forkhead box protein G1A; Forkhead box protein G1B; Forkhead box protein G1C; Forkhead-related protein FKHL1; Forkhead-related protein FKHL2; Forkhead-related protein FKHL3

Alternative UPACC:

P55316; A6NFY2; P55315; Q14488; Q86XT7

Background:

Forkhead box protein G1, known by alternative names such as Brain factor 1 and Forkhead-related protein FKHL1, plays a pivotal role in brain development and the establishment of the telencephalon's regional subdivision. Its involvement in transcription repression underscores its significance in neurodevelopment.

Therapeutic significance:

Linked to the congenital variant of Rett syndrome, Forkhead box protein G1's mutation highlights its critical role in severe neurodevelopmental disorders. Understanding its function could pave the way for innovative therapeutic strategies targeting early-onset neurodevelopmental conditions.